This Company Is Developing Novel Treatments For Difficult To Treat CNS Cancers

Norman LaFrance, MD, CMO & Senior VP, and Melissa Moore, PhD, VP of Clinical Research for Plus Therapeutics Inc. PSTV were recently interviewed by Benzinga.

Plus Therapeutics is a clinical stage pharmaceutical company that has developed a radiotherapeutic platform with the potential to lengthen and improve the lives of adults and children with challenging cancers. 

The company takes a unique approach in combining radiation particles with nanoliposomes and alginate microspheres; it hopes to target cancer more safely, precisely and effectively than other approaches in radiation therapy and oncology.

Watch the full interview here:

Featured photo by National Cancer Institute on Unsplash.

This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice.